# Poseida Therapeutics (stock symbol: PSTX) Logo in transparent PNG and SVG formats

## Poseida Therapeutics Logo large

### Poseida Therapeutics Logo large Download PNG (41.87 KB)

![Poseida Therapeutics Logo large Download PNG (41.87 KB)](/img/orig/PSTX_BIG-bb5e63e6.png)

### Poseida Therapeutics Logo large Download SVG (5.77 KB)

![Poseida Therapeutics Logo large Download SVG (5.77 KB)](/img/orig/PSTX_BIG-d5ad31a2.svg)

## Poseida Therapeutics Logo icon format

### Poseida Therapeutics Logo icon format Download PNG (75.59 KB)

![Poseida Therapeutics Logo icon format Download PNG (75.59 KB)](/img/orig/PSTX-7f637bde.png)

### Poseida Therapeutics Logo icon format Download SVG (1.73 KB)

![Poseida Therapeutics Logo icon format Download SVG (1.73 KB)](/img/orig/PSTX-c5c98907.svg)

## Poseida Therapeutics Logo large for dark backgrounds

### Poseida Therapeutics Logo large for dark backgrounds Download PNG (26.16 KB)

![Poseida Therapeutics Logo large for dark backgrounds Download PNG (26.16 KB)](/img/orig/PSTX_BIG.D-abd8b100.png)

### Poseida Therapeutics Logo large for dark backgrounds Download SVG (5.62 KB)

![Poseida Therapeutics Logo large for dark backgrounds Download SVG (5.62 KB)](/img/orig/PSTX_BIG.D-8ff130af.svg)

## Poseida Therapeutics Logo icon format for dark backgrounds

### Poseida Therapeutics Logo icon format for dark backgrounds Download PNG (45.24 KB)

![Poseida Therapeutics Logo icon format for dark backgrounds Download PNG (45.24 KB)](/img/orig/PSTX.D-1db8b2ec.png)

### Poseida Therapeutics Logo icon format for dark backgrounds Download SVG (1.61 KB)

![Poseida Therapeutics Logo icon format for dark backgrounds Download SVG (1.61 KB)](/img/orig/PSTX.D-0738fb6c.svg)

## About Poseida Therapeutics

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

1. Website domain: poseida.com
2. Employees: 290
3. Marketcap: $0.22 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
- [x] ðŸ§¬ Genomics
- [x] ðŸ§¬ Gene therapy
